In the United States, the U.S. Food and Drug Administration recently approved a new, higher-dose version of the obesity treatment Wegovy, which is produced by Novo Nordisk. This new dosage of semaglutide, 7.2 milligrams, is set to be available at pharmacies soon, marking a significant increase from the prior highest dose of 2.4 milligrams. The application for this higher dose went through the FDA's accelerated review program, resulting in a decision that's made just 54 days after the initial review request. The new dosage aims to address challenges faced by some patients who have not met their weight loss objectives with lower doses, as evidenced by studies indicating that the previous dosage was effective for many, but not all patients. The European drug regulators also endorsed the 7.2-milligram version earlier in February, reflecting a growing awareness of the need for more effective obesity treatments. Many patients may benefit particularly from the increase in dose, as noted by Dr. Jody Dushay, an obesity expert at Harvard Medical School. She points out that this higher formulation could be particularly useful for individuals who tolerate the existing lower dose yet experience insufficient weight loss. However, potential side effects remain a significant concern: clinical trials revealed that more than 70% of participants experienced nausea, vomiting, and constipation, with noticeable adverse effects like unpleasant skin sensations occurring in some patients. This high incidence of side effects raises questions among experts regarding how well the higher dose will be tolerated in real-world use. Although the 7.2-milligram dose shows promise for weight loss, the jump from 2.4 to 7.2 milligrams is substantial, leading to considerations about the safety and efficacy of such an increase without an intermediate step. Clinical findings indicate that serious adverse events were documented in nearly 7% of patients taking the new higher dose, which was an improvement compared to the 11% seen in the lower dose group, though still higher than those on a placebo. The new Wegovy dosage suggests a developing trend in obesity treatment, aimed at providing enhanced solutions for patients struggling with weight management.